- Conditions
- Post-Acute COVID-19 Syndrome
- Interventions
- Baricitinib 4 MG, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 65
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Interventions
- Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
- Drug
- Lead sponsor
- Jeffrey Curtis
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
- Conditions
- Cutaneous Lichen Planus
- Interventions
- Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
- Drug
- Lead sponsor
- Aaron R. Mangold
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Cardiac Sarcoidosis
- Interventions
- Baricitinib (LY3009104) 4 mg
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Arthritis, Rheumatoid
- Interventions
- LY3009104, Placebo, Methotrexate
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 31
- States / cities
- Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 45
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Major Depressive Disorder
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Depressive Symptoms, Cognitive Symptom
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 30 Years to 55 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Kidney Diseases
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
- Interventions
- Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Rheumatoid Arthritis
- Interventions
- INCB028050, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlestown, Massachusetts
- Conditions
- Diabetic Kidney Disease
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 35
- States / cities
- Lancaster, California • San Diego, California • Torrance, California + 32 more
- Conditions
- Alopecia Areata
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 29 more
- Conditions
- Covid19, Corona Virus Infection
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Detroit, Michigan • Cleveland, Ohio
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Baricitinib, cDMARD
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 684 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 48
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more
- Conditions
- HIV Infection, HIV
- Interventions
- Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV, Depression, Anhedonia
- Interventions
- Baricitinib, Placebo
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 588 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 47
- States / cities
- Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
- Conditions
- Liver Diseases, Hepatic Insufficiency
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida